Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Has Average Target Price of $6.57

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has earned an average rating of “Moderate Buy” from the nine analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $6.57.

Several brokerages have issued reports on NMRA. Royal Bank Of Canada cut their target price on shares of Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Weiss Ratings raised Neumora Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, September 25th. Wall Street Zen cut Neumora Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 10th. Finally, HC Wainwright reiterated a “buy” rating on shares of Neumora Therapeutics in a report on Tuesday, July 28th.

Insiders Place Their Bets

In related news, insider Daljit Singh Aurora sold 91,690 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1.50, for a total value of $137,535.00. Following the completion of the sale, the insider directly owned 48,750 shares of the company’s stock, valued at approximately $73,125. This represents a 65.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 453,833 shares of company stock worth $701,219 over the last quarter. 26.94% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Neumora Therapeutics

A number of institutional investors have recently bought and sold shares of the business. HBK Sorce Advisory LLC purchased a new stake in shares of Neumora Therapeutics in the second quarter worth approximately $26,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Neumora Therapeutics during the second quarter worth approximately $44,000. AMG National Trust Bank acquired a new stake in shares of Neumora Therapeutics during the second quarter worth approximately $74,000. SkyOak Wealth LLC boosted its holdings in shares of Neumora Therapeutics by 50.0% during the first quarter. SkyOak Wealth LLC now owns 150,000 shares of the company’s stock worth $292,000 after purchasing an additional 50,000 shares during the period. Finally, Bank of America Corp DE boosted its holdings in shares of Neumora Therapeutics by 72.8% during the first quarter. Bank of America Corp DE now owns 176,927 shares of the company’s stock worth $345,000 after purchasing an additional 74,518 shares during the period. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Neumora Therapeutics Stock Performance

Shares of NASDAQ:NMRA opened at $0.47 on Wednesday. The company has a debt-to-equity ratio of 1.19, a quick ratio of 4.50 and a current ratio of 4.50. Neumora Therapeutics has a 52 week low of $0.32 and a 52 week high of $3.65. The firm has a 50 day simple moving average of $0.98 and a 200 day simple moving average of $1.51.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. Research analysts forecast that Neumora Therapeutics will post -0.83 EPS for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for disorders of the brain. The company combines neuroscience research with data science, including its proprietary MAP platform, to identify patient subgroups, discover potential drug targets and support the development of therapies for neurological and neuropsychiatric conditions.

Neumora’s lead investigational product is navacaprant, an oral, selective kappa opioid receptor antagonist being evaluated for major depressive disorder.